Finding innovative solutions for unmet medical needs is at the heart of what we do. Our ideas and research help save lives.
Not a healthcare professional? Visit the Roche New Zealand website.
Our aim is for every person who needs our medicines and diagnostic tests to be able to benefit from them. Discover our areas of focus at roche.co.nz.
VABYSMO® (faricimab) is funded by PHARMAC for the treatment of adults with neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Special Authority criteria apply.
OCREVUS® SC (ocrelizumab subcutaneous) is funded by PHARMAC for patients with RMS and PPMS who meet predefined criteria. Special Authority criteria apply.
Phesgo® (pertuzumab & trastuzumab) Subcutaneous (SC) is funded by PHARMAC for patients with HER2-positive metastatic breast cancer who meet predefined criteria. Special Authority criteria apply.
Rozlytrek® (entrectinib) is funded by PHARMAC for patients with ROS1-positive, locally advanced or metastatic NSCLC. Special Authority criteria apply.